

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



Abbisko Cayman Limited

和譽開曼有限責任公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2256)

**VOLUNTARY ANNOUNCEMENT
INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER,
THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER AND
THE CHAIRMAN OF THE BOARD OF THE COMPANY AND UPDATES ON
ON-MARKET SHARE REPURCHASE**

This announcement is made by Abbisko Cayman Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference are made to the announcements of the Company dated March 4, 2025, March 13, 2025 and May 6, 2025 in relation to the increase in shareholding of the Company by Dr. Xu Yao-Chang (“**Dr. Xu**”), the founder, the executive director, the chief executive officer of the Company and the chairman of the board (the “**Board**”) of directors (the “**Directors**”) of the Company. The Board was further informed by Dr. Xu, that Dr. Xu purchased a total of 17,000 ordinary shares of the Company (the “**Shares**”) in the open market on June 12, 2025 at an average price of approximately HK\$10.40 per Share, representing approximately 0.0025% of the total issued Shares of the Company. Immediately following the purchase, Dr. Xu is interested in an aggregate of 80,034,980 Shares, representing approximately 11.77% of the total issued Shares of the Company as at the date of this announcement. Dr. Xu has accumulatively purchased a total of 132,000 Shares in the open market from March 3, 2025 to the date of this announcement.

As advised by Dr. Xu, he is confident about the business prospect and growth of the Group. Subject to applicable laws and regulatory requirements, Dr. Xu does not rule out the possibility that he may further increase his shareholding in the Company as and when appropriate.

Reference is also made to the announcement of the Company dated March 3, 2025 in relation to the Board’s approval of an amount of no more than HK\$200 million to repurchase Shares of the Company on-market (the “**Share Repurchase Plan**”). The Board is of the view that the current trading price of the Shares undervalues the Company’s intrinsic value and business potential. Under the Share Repurchase Plan, the Company has repurchased 8,695,000 Shares (representing approximately 1.28% of the total issued Shares of the Company as at the date of this announcement) from March 3, 2025 to the date of this announcement, with a total consideration of HK\$66.76 million.

Based on the information available to the Company and to the knowledge of the Board, following the completion of the increase in shareholding and as at the date of this announcement, the Company has maintained a sufficient public float of its issued Shares in compliance with the applicable laws, rules and provisions, including the Rule 8.08 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”); and the increase in shareholding was conducted in compliance with the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 of the Listing Rules adopted by the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, June 12, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.